EUCTR2020-001317-20-IT进行中（未招募）1 期
A Phase Ib/IIa, randomized, double-blind placebo-controlled, multicenter adaptive design clinical trial to evaluate the immune signature of the treatment with the Imotope™ IMCY-0098 and its effect on the preservation of beta-cell function in young adult and adolescent patients with a recent onset Type 1 diabetes - IMPACT
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Imcyse SA
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •(1)Have given written informed consent for adult participants and adolescent participant's parent(s). Have given written informed assent for adolescent participants.
- •(2)Age at screening:
- •- Step 1 will include participants aged greater than or equal to 18 years and < 45 years at the time of consent
- •- Step 2 will include participants aged greater than or equal to 12 years and <45 years at the time of assent/consent.
- •(3)Must have a diagnosis of T1D of within maximum 9 weeks duration at screening (date of the first insulin injection)(4)Must have at least one or more diabetes-related autoantibodies present at screening (GAD65, IA-2, or ZnT8)
- •(5)Must have random C-peptide levels greater than or equal to 200 pmol/L measured at screening
- •(6)Must be HLA DR4 positive
- •(7)Must be willing to comply with intensive diabetes management
- •(8)Be treated with insulin therapy in accordance with local standard of care
- •(9)Males with reproductive potential must agree to use adequate contraception up to 90 days after the completion of the last treatment.
- •This includes:
- •- Barrier contraception (condom and spermicide) or
- •- True abstinence (where this is in accordance with the participants preferred and usual lifestyle)
- •(10)All females must have a negative serum pregnancy test at screening. Women sexually active and of childbearing potential must agree to use a highly effective contraception method from screening up to 90 days after last treatment with the investigational product
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 54
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •(1)Clinically significant abnormal full blood count (FBC), renal function or liver function at screening, including
- •a.Be immunodeficient or have clinically significant chronic lymphopenia:
- •Leukopenia (< 3,000 leukocytes /µL), neutropenia (<1,500 neutrophils/µL), lymphopenia (<800 lymphocytes/µL), or thrombocytopenia (<100,000 platelets/µL)
- •b.Evidence of renal dysfunction with creatinine greater than 1.5 times the upper limit of normal
- •c.Evidence of liver dysfunction with aspartate aminotransferase (AST) or alanine transaminase (ALT) greater than 3 times the upper limits of normal. Patients with elevated unconjugated bilirubin (Gilbert's syndrome) are eligible if bilirubin is less than or equal to 3 times the upper limits of normal and hepatic enzymes and function are otherwise normal (AST/ALT/Alkaline phosphatase within ULN), and there is no evidence of hemolysis.
- •(2)Have signs or symptoms of serious active infection requiring IV antibiotics and/or hospitalization at study entry
- •(3)Has received any live, attenuated vaccine within 3 months prior to the first planned administration of the study product (which includes, but is not limited to: oral poliomyelitis vaccine, measles-mumps-rubella vaccine, yellow fever vaccine, Japanese encephalitis vaccine, dengue vaccine, rotavirus vaccine, varicella vaccine, live-attenuated zoster vaccine, Bacillus Calmette-Guérin [BCG] vaccine, oral typhoid vaccine)
- •(4)Be currently pregnant or lactating, or anticipate getting pregnant until at least 24 weeks after last study drug administration
- •(5)Require the use of immunosuppressive agents including chronic use of systemic steroids
- •(6)Have evidence of current or past human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection
- •(7)Presence of any uncontrolled disease (including uncontrolled autoimmune disease) or abnormal clinical laboratory results that may interfere with study conduct as judged by the investigator
- •(8)History of, or current malignancy (except excised basal cell skin cancer)
- •(9)Current or ongoing use of non-insulin pharmaceuticals that affect glycaemic control within the 7 days prior to screening visit
- •(10)Active participation in another T1D treatment study or any investigational intervention study in the previous 30 days
- •(11)Known hypersensitivity to any component of the drug product
- •(12)CRO or Sponsor employees or employees under the direct supervision of the Investigator and/or involved directly in the study.
研究者
相似试验
进行中（未招募）
1 期
IMCY-0098 Proof of ACtion in Type 1 Diabetes - IMPACT StudyMedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 1 DiabetesEUCTR2020-001317-20-SEImcyse SA84
进行中（未招募）
1 期
IMCY-0098 Proof of ACtion in Type 1 Diabetes - IMPACT StudyMedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 1 DiabetesEUCTR2020-001317-20-GBImcyse SA84
进行中（未招募）
1 期
Cannabidiol: a novel intervention for cannabis use problems?'Moderate cannabis use disorder' as defined by the diagnostic criteria in DSM-5 (published in May 2013), similar to the previous term 'cannabis dependence' (DSM-4).MedDRA version: 16.0Level: LLTClassification code 10007177Term: Cannabis dependenceSystem Organ Class: 100000004873EUCTR2013-000361-36-GBJoint Research Office82
进行中（未招募）
1 期
Efficacy and safety of BI 655066/ABBV-066 (risankizumab) in patients with severe persistent asthma.Severe AsthmaEUCTR2014-004932-20-PLBoehringer Ingelheim RCV GmbH & CoKG200
进行中（未招募）
1 期
Efficacy and safety of BI 655066 in patients with severe persistent asthmaEUCTR2014-004932-20-ITBOEHRINGER-INGELHEIM ITALIA S.P.A.369